Clinical Trial Update: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating BR790 in combination with Anlotinib for adults with advanced non-small cell lung cancer in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• BR790

Snippet

Sponsor: Shanghai Gopherwood Biotech Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN